Holen Sie sich die Stockscreener-App
31.82
1.73%
0.54
Handel nachbörslich:
31.82
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
19.53%
166.50
|
139.29 | 139.49 | 147.03 | 108.83 |
Operating Expenses
|
2.78%
274.38
|
282.23 | 271.48 | 263.39 | 274.18 |
| Benefits Costs and Expenses |
2.96%
280.50
|
289.06 | 272.71 | 277.77 | 279.06 |
| Costs And Expenses |
2.96%
280.50
|
289.06 | 272.71 | 277.77 | 279.06 |
| Operating Income/Loss |
24.52%
-107.89
|
-142.94 | -131.99 | -116.36 | -165.35 |
| Income/Loss From Continuing Operations Before Tax |
23.88%
-114.00
|
-149.77 | -133.21 | -130.74 | -170.23 |
| Income Tax Expense/Benefit |
27.71%
0.947
|
1.31 | 0.303 | 0.858 | 0.455 |
| Income/Loss From Continuing Operations After Tax |
23.91%
-114.95
|
-151.08 | -133.52 | -131.60 | -170.68 |
|
Net Income/Loss
|
23.91%
-114.95
|
-151.08 | -133.52 | -131.60 | -170.68 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
2.26%
98.46
|
96.29 | 95.49 | 86.58 | 84.29 |
| Diluted Average Shares |
2.26%
98.46
|
96.29 | 95.49 | 86.58 | 84.29 |
| Basic Earnings Per Share |
25.48%
-1.17
|
-1.57 | -1.40 | -1.52 | -2.03 |
| Diluted Earnings Per Share |
25.48%
-1.17
|
-1.57 | -1.40 | -1.52 | -2.03 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):